Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Chimerix Inc (CMRX)

Chimerix Inc (CMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Chimerix Inc 2505 MERIDIAN PARKWAY SUITE 100 DURHAM NC 27713 USA

www.chimerix.com P: 919-806-1074 F: 919-806-1146

Description:

Chimerix, Inc. engages in the discovery, development and commercialization of oral antiviral therapeutics for various medical needs. The Company is developing various product candidates for the treatment of dsDNA viruses, HIV, hepatitis C, influenza and smallpox which are under different phases of clinical development. It is also screening our proprietary Chimerix Chemical Library for compounds with activity against dengue virus, malaria and tuberculosis. Chimerix, Inc. is headquartered in Durham, North Carolina.

Key Statistics

Overview:

Market Capitalization, $K 83,170
Enterprise Value, $K 55,640
Shares Outstanding, K 89,210
Annual Sales, $ 320 K
Annual Net Income, $ -82,100 K
Last Quarter Sales, $ 10 K
Last Quarter Net Income, $ -23,990 K
EBIT, $ -96,070 K
EBITDA, $ -102,850 K
60-Month Beta 1.15
% of Insider Shareholders 10.00%
% of Institutional Shareholders 45.42%
Float, K 80,289
% Float 90.00%
Short Volume Ratio 0.33

Growth:

1-Year Return -27.51%
3-Year Return -89.09%
5-Year Return -63.86%
5-Year Revenue Growth -95.57%
5-Year Earnings Growth 34.97%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.20 on 02/29/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm -0.96
EPS Growth vs. Prev Qtr 25.93%
EPS Growth vs. Prev Year 16.67%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

CMRX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -37.93%
Return-on-Assets % -35.02%
Profit Margin % -25,656.25%
Debt/Equity 0.00
Price/Sales 248.91
Price/Cash Flow N/A
Price/Book 0.42
Book Value/Share 2.34
Interest Coverage -2.34
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar